DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter

Information source: Carmel Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Combigan (Combination of Brimonidine and Timolol) (Drug); Timolol (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: Carmel Medical Center

Official(s) and/or principal investigator(s):
Orna Geyer, MD, Principal Investigator, Affiliation: Carmel Medical Center

Overall contact:
Orna Geyer, Professor, Phone: 97248250926, Email: orna_geyer@clalit.org.il

Summary

In this study we will explore the combined effect of Brimonidine and Timolol 0. 5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker has not been studied.

Clinical Details

Official title: The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Pupil diameter

Detailed description: In this study we will explore the combined effect of Brimonidine and Timolol 0. 5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil, however the combined effect of alpha agonist and beta blocker has not been studied. The study subjects will be examined twice, two weeks apart. On the first exam the subject will receive Combigan eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0. 5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.

Eligibility

Minimum age: 18 Years. Maximum age: 30 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy adults subjects with no ocular pathology

- Non pregnant women

- Normal pupil response

Exclusion Criteria:

- Chronic topical treatment

- Systemic medication affecting autonomic nerve system

- History of intra-ocular surgery

- Irregular pupil

- History of ocular neurological or severe cardio-vascular disease

Locations and Contacts

Orna Geyer, Professor, Phone: 97248250926, Email: orna_geyer@clalit.org.il

Carmel Medical Center, Haifa 34362, Israel; Not yet recruiting
Zina Goldbaum, Phone: 97248250441, Email: zinago@clalit.org.il
Additional Information

Starting date: August 2014
Last updated: August 28, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017